[go: up one dir, main page]

UY26296A1 - Tratamiento medicamentoso del síndrome de piernas inquietas - Google Patents

Tratamiento medicamentoso del síndrome de piernas inquietas

Info

Publication number
UY26296A1
UY26296A1 UY26296A UY26296A UY26296A1 UY 26296 A1 UY26296 A1 UY 26296A1 UY 26296 A UY26296 A UY 26296A UY 26296 A UY26296 A UY 26296A UY 26296 A1 UY26296 A1 UY 26296A1
Authority
UY
Uruguay
Prior art keywords
legs syndrome
inquiet
drug treatment
rls
monotherapy
Prior art date
Application number
UY26296A
Other languages
English (en)
Inventor
Dr Hans-Michael Brecht
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of UY26296A1 publication Critical patent/UY26296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

El invento se refiere a una nueva combinación de sutancias activas para el tratamiento más eficaz del síndrome de piernas inquietas (RLS), que consta de un agente agonista alfa 2 y de otro neuro-psicofármaco que reduce los síntomas del RLS como una monoterapia.
UY26296A 1999-08-19 2000-08-16 Tratamiento medicamentoso del síndrome de piernas inquietas UY26296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19938823A DE19938823A1 (de) 1999-08-19 1999-08-19 Medikamentöse Behandlung des Restless Leg Syndroms

Publications (1)

Publication Number Publication Date
UY26296A1 true UY26296A1 (es) 2001-04-30

Family

ID=7918572

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26296A UY26296A1 (es) 1999-08-19 2000-08-16 Tratamiento medicamentoso del síndrome de piernas inquietas

Country Status (21)

Country Link
US (1) US20010053777A1 (es)
EP (1) EP1210076A2 (es)
JP (1) JP2003513014A (es)
KR (1) KR20020020273A (es)
CN (1) CN1368878A (es)
AR (1) AR025329A1 (es)
AU (1) AU6836500A (es)
BR (1) BR0013355A (es)
CA (1) CA2382648A1 (es)
CO (1) CO5190708A1 (es)
CZ (1) CZ2002516A3 (es)
DE (1) DE19938823A1 (es)
IL (1) IL147643A0 (es)
MX (1) MXPA02001295A (es)
NO (1) NO20020792D0 (es)
PE (1) PE20010738A1 (es)
PL (1) PL364871A1 (es)
SK (1) SK2452002A3 (es)
TR (1) TR200200450T2 (es)
UY (1) UY26296A1 (es)
WO (1) WO2001013903A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
NZ505193A (en) 1997-12-22 2003-03-28 Euro Celtique S Opioid agonist/antagonist combinations
JP2004502651A (ja) * 2000-04-21 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 線維筋痛症および慢性疲労症候群の治療
ATE312608T1 (de) * 2000-04-21 2005-12-15 Pharmacia & Upjohn Co Llc Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
CN100398154C (zh) * 2001-03-30 2008-07-02 东丽株式会社 精神神经疾病治疗药
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
PT1492505E (pt) 2002-04-05 2015-10-06 Euro Celtique Sa Preparação farmacêutica contendo oxicodona e naloxona
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
CA2487541A1 (en) * 2002-06-19 2003-12-31 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
ATE295726T1 (de) 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
WO2008079727A2 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
EP2363116A1 (en) * 2008-06-25 2011-09-07 US Worldmeds LLC Sustained-release formulations comprising lofexidine for oral delivery
AU2010223323B2 (en) 2009-03-10 2013-07-04 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
ES2765200T3 (es) * 2012-06-11 2020-06-08 Psychogenics Inc Tratamiento de efectos secundarios de trastornos motores y de movimiento asociados a tratamientos de la enfermedad de Parkinson
EP3024461B1 (en) 2013-07-23 2020-05-13 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
JP6310070B2 (ja) 2013-10-07 2018-04-11 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
EP3512600A4 (en) * 2016-09-13 2020-05-27 Mindlab LLC DRUG COMBINATIONS AND TREATMENT OF RESTLESS LEG SYNDROME
RU2723761C1 (ru) 2016-10-31 2020-06-17 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы устранения боли с использованием устройств для трансдермальной доставки дексмедетомидина
SI3906927T1 (sl) * 2020-05-04 2022-08-31 Bioprojet Pharma Uporaba delnih agonistov dopamina D3 za zdravljenje motenj centralnega živčnega sistema
CN115154448B (zh) * 2022-08-04 2024-01-30 谭竞 一种治疗不宁腿综合征的药物及其制备方法和应用
WO2025255416A1 (en) * 2024-06-05 2025-12-11 TMTRx, Inc. Fentanyl and fentanyl analogue overdose reversal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
DE19749724A1 (de) * 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
CA2382648A1 (en) 2001-03-01
EP1210076A2 (de) 2002-06-05
AR025329A1 (es) 2002-11-20
JP2003513014A (ja) 2003-04-08
BR0013355A (pt) 2002-04-30
PE20010738A1 (es) 2001-07-16
NO20020792L (no) 2002-02-18
CN1368878A (zh) 2002-09-11
WO2001013903A3 (de) 2001-08-23
TR200200450T2 (tr) 2002-08-21
WO2001013903A2 (de) 2001-03-01
SK2452002A3 (en) 2002-06-04
IL147643A0 (en) 2002-08-14
US20010053777A1 (en) 2001-12-20
AU6836500A (en) 2001-03-19
DE19938823A1 (de) 2001-02-22
NO20020792D0 (no) 2002-02-18
CO5190708A1 (es) 2002-08-29
PL364871A1 (en) 2004-12-27
KR20020020273A (ko) 2002-03-14
MXPA02001295A (es) 2002-08-12
CZ2002516A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
ECSP003652A (es) TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
AR046510A1 (es) Composicion de un antagonista de vegf y un agente anti-proliferativo
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR048210A1 (es) Un agente preventivo para la vasculitis.
DK1143989T3 (da) Exendiner til glucagonundertrykkelse
ECSP034629A (es) Combinacion de agonista de gaba e inhibidores de aldosa-reductasa
UY26293A1 (es) "combinación de sustancias activas con clonidina."
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
WO2003105751A3 (en) Novel curcumin derivatives
UY27401A1 (es) Método para el tratamiento del insomnio primario
ES2173871T3 (es) Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1.
CO5540370A2 (es) Comprimido que comprende cetirizina y pseudoefredina
AR046853A1 (es) Mezclas insecticidas que contienen triflumuron con actividad sinergica
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
ECSP003622A (es) Tratamiento medicamentoso del sindrome de piernas inquietas
SE0000303D0 (sv) Novel compounds
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.
MX2022007936A (es) Agente profilactico y/o terapeutico para la prostatitis cronica/sindrome de dolor pelvico cronico.
SE0203817D0 (sv) New composition
ATE406880T1 (de) Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110505